Table II.
Univariate analysis for cancer-specific survival following development of liver metastasis (LM).
| Clinicopathological factors | P-value |
|---|---|
| Agea, years (60> vs. 60≤) | 0.1172 |
| Sarcomatoid differentiationb (+ vs. −) | 0.0067 |
| Histological grade 3b (+ vs. −) | 0.2898 |
| Fuhrman gradeb (<3 vs. 4) | 0.4066 |
| MVIb (+ vs. −) | 0.9872 |
| Tumor necrosisb (+ vs. −) | 0.8618 |
| Tumor sizeb (<10 vs. ≥10 cm) | 0.9160 |
| pT1 or 2 vs. pT3 or 4b | 0.3196 |
| Presence of LM at Nx (yes vs. no) | 0.0992 |
| No. of LM at presentation (1 vs. ≥2) | 0.4447 |
| ECOG PSa (0 or 1 vs. 2≤) | 0.0002 |
| CRPa (<1.0 vs. ≥1.0 mg/dl) | 0.0019 |
| LDHa, IU/l (<338 vs. ≥338) | 0.9019 |
| Hemoglobina (anemia vs. normal) | 0.1704 |
| Platelet counta (<35×104 vs. ≥35×104/mm3) | 0.3434 |
| Corrected calciuma (<10 vs. ≥10 mg/dl) | 0.0100 |
| LM only (yes vs. no) | 0.0367 |
| Tyrosine kinase inhibitors (yes vs. no) | 0.8848 |
| Cytokine therapy (yes vs. no) | 0.7278 |
| Local treatment (yes vs. no) | 0.8373 |
| Hepatic resection (yes vs. no) | 0.0528 |
| Interval from Nx to LM, months (<24 vs. ≥24) | 0.4218 |
a
At the time of LM.
b
Primary lesion. MVI, microvascular invasion; Nx, nephrectomy; ECOG PS, Eastern Cooperative Oncology Group performance status; CRP, C-reactive protein; LDH, lactate dehydrogenase.